Zydus Lifesciences Limited — Updates, 07-08-2025: Press Release

Zydus Lifesciences has secured its first approval from Health Canada for ZDS-Varenicline tablets (0.5 & 1 mg). This significant business development marks the group's initial entry into the Canadian market with a drug aiding smoking cessation. Production will be handled at Zydus's SEZ unit in Ahmedabad. The Canadian market for Varenicline tablets had annual sales of approximately 91.5 Cr, presenting a new revenue opportunity and potential for enhanced manufacturing utilization for Zydus.